Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate

Phase 4CompletedNCT01666041

Gachon University Gil Medical Center120 enrolled

Overview

The investigators hypothesize that fenofibrate/omega will improve insulin resistance compared with fenofibrate

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

120

Conditions

Hypertriglyceridemia

Interventions

placeboDRUG

fenofibrate/omegaDRUG

fenofibrateDRUG

Eligibility

Sex: ALLMin age: 25 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hypertriglyceridemia Exclusion Criteria: * moderate or severe hypertension, uncontrolled diabetes (HbA1c \> 9%), nephrotic syndrome, hypothyroidism, coronary artery disease, or peripheral vascular disease

Locations (1)

Gil Medical Center

Incheon, South Korea

Outcomes

Primary Outcomes

flow-mediated dilation

Time frame: 8 weeks of treatment

Secondary Outcomes

insulin resistance

Time frame: 8 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.